SOURCE: CDEX, Inc.

November 05, 2007 09:00 ET

CDEX, Inc. Announces International Expansion of Its ValiMed™ Marketing Team

Mr. Pascal Pouligny Joins CDEX, Inc. as Vice President of International Sales and Marketing to Launch ValiMed™ Into the International Health Care and Hospital Markets

TUCSON, AZ and PARIS--(Marketwire - November 5, 2007) - CDEX, Inc. (OTCBB: CEXI) follows up on its record quarter in ValiMed™ sales/leases to U.S. hospitals by announcing that Mr. Pascal Pouligny has joined CDEX as Vice President of International Sales and Marketing to launch ValiMed into the International health care and hospital markets. The ValiMed Medication Validation System uses Enhanced Photoemission Spectroscopy to quickly validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the CDEX Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

Mr. Pouligny has served in senior management positions in a number of companies over the past 20 years, with a primary focus on international sales and marketing to the healthcare market. He has successfully launched new medical products and services into the European, Middle East, and Asian markets for startup and major companies. (Mr. Pouligny's bio is on the CDEX web site at www.cdex-inc.com.)

"ValiMed presents an innovative and proven technology that is needed in the world healthcare markets," said Mr. Pouligny. "I look forward to working with the CDEX team as we launch this product into the international marketplace."

"Pascal is a well respected and seasoned executive who has successfully launched many medical products and services throughout the world," said Malcolm Philips, CDEX CEO. "We look forward to his leadership in establishing reference testing partners, developing channel sales networks and implementing the sales/marketing strategy first for Europe and then beyond."

About CDEX, Inc.

CDEX, Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact Malcolm Philips (mphilips@cdex-inc.com) or Stuart Poteet (spoteet@cdex-inc.com) at 520.745.5172 X 210 or 202.

ANY STATEMENTS MADE IN THIS PRESS RELEASE WHICH CONTAIN INFORMATION THAT IS NOT HISTORICAL ARE ESSENTIALLY FORWARD-LOOKING, AS THAT TERM IS DEFINED IN THE FEDERAL SECURITIES LAWS. MANY FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF WORDS SUCH AS "EXPECTS," "PLANS," "MAY," "ANTICIPATES," "BELIEVES," "SHOULD," "INTENDS," "ESTIMATES," AND OTHER WORDS OF SIMILAR MEANING. THESE STATEMENTS ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT CANNOT BE PREDICTED OR QUANTIFIED AND, CONSEQUENTLY, ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE EXPRESSED OR IMPLIED BY SUCH FORWARD-LOOKING STATEMENTS. SUCH RISKS AND UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE ABILITY OF THE COMPANY TO RAISE CAPITAL TO FINANCE THE DEVELOPMENT OF ITS PRODUCTS, THE EFFECTIVENESS, PROFITABILITY AND MARKETABILITY OF THOSE PRODUCTS, THE ABILITY OF THE COMPANY TO PROTECT ITS PROPRIETARY INFORMATION, THE ESTABLISHMENT OF AN EFFICIENT CORPORATE OPERATING STRUCTURE AS THE COMPANY GROWS AND, OTHER RISKS DETAILED FROM TIME-TO-TIME IN FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION. THERE IS NO OBLIGATION TO PUBLICLY UPDATE ANY FORWARD-LOOKING STATEMENTS.

Contact Information